An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas - 19/04/18
Abbreviations used : aBCC, AE, PI3K, PFS, SI
Funding sources: Study funded as an investigator initiated research award by Novartis to Dr Chang. |
|
Conflicts of interest: Dr Chang is a clinical investigator for studies sponsored by Novartis. Other authors have no conflicts of interest to disclose. |
|
Previously presented: This study was presented at the Society for Investigative Dermatology in Portland, Oregon, in April 26-29, 2017. |
|
Reprints not available from the authors. |
Vol 78 - N° 5
P. 1011 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?